Note 6   Acquisition Palomar Medical Technologies, Inc. On June 24, 2013, Cynosure acquired Palomar Medical Technologies, Inc. (Palomar). The acquisition has complemented and broadened Cynosure s product lineup with the addition of Palomar s intense pulsed light, fractional laser and diode aesthetic systems, doubled the number of patents in Cynosure s portfolio and enhanced Cynosure s global distribution network. As a result of the transaction, former Palomar stockholders, in the aggregate, received for their shares of Palomar common stock $145.8 million in cash and 6.0 million shares of Cynosure Class A common stock. The total consideration was valued at $287.2 million, based upon the closing price of Cynosure Class A common stock on June 24, 2013. This acquisition was considered a business acquisition for accounting purposes. The goodwill recognized is attributable to synergies associated with the Palomar technology which has been integrated with Cynosure s product portfolio and distributed throughout the U.S. and international distribution channels. Cynosure retained an independent valuation firm to assess the fair value of the identifiable intangible assets and certain tangible assets acquired, and also assessed the fair value of other assets acquired and liabilities assumed. Pro forma financial information was filed with the SEC within the applicable time period. Cynosure has allocated the purchase price to the net tangible and intangible assets based on their estimated fair values as of June 24, 2013. During the six months ended June 30, 2014, Cynosure completed its purchase accounting estimates of the assets acquired and liabilities assumed in regards to the acquisition of Palomar, and as a result, increased goodwill $4.1 million from December 31, 2013 to June 30, 2014, due primarily to adjustments to the inventory reserve of $3.8 million, reclassification of certain tax reserves, increases to accounts payable and decreases to accrued expenses related to the opening balance sheet. The adjustments related t